Thymosin alpha 1 is a peptide naturally occurring in the thymus that has long been recognized for modifying,enhancing,and restoring immune function.Thymosin alpha 1 has been utilized in the treatment of immunocompromi...Thymosin alpha 1 is a peptide naturally occurring in the thymus that has long been recognized for modifying,enhancing,and restoring immune function.Thymosin alpha 1 has been utilized in the treatment of immunocompromised states and malignancies,as an enhancer of vaccine response,and as a means of curbing morbidity and mortality in sepsis and numerous infections.Studies have postulated that thymosin alpha 1 could help improve the outcome in severely ill corona virus disease 2019 patients by repairing damage caused by overactivation of lymphocytic immunity and how thymosin alpha 1 could prevent the excessive activation of T cells.In this review,we discuss key literature on the background knowledge and current clinical uses of thymosin alpha 1.Considering the known biochemical properties including antibacterial and antiviral properties,timehonored applications,and the new promising findings regarding the use of thymosin,we believe that thymosin alpha 1 deserves further investigation into its antiviral properties and possible repurposing as a treatment against severe acute respiratory syndrome coronavirus-2.展开更多
目的探讨苦参素联合胸腺肽α1治疗失代偿期肝硬化的抗病毒疗效。方法将42例失代偿期丙型肝炎肝硬化患者按照随机数字表分成2组,对照组(n=21)给予保肝、白蛋白基础治疗,观察组(n=21)在基础治疗之上加用苦参素、胸腺肽α1治疗,疗程48周。...目的探讨苦参素联合胸腺肽α1治疗失代偿期肝硬化的抗病毒疗效。方法将42例失代偿期丙型肝炎肝硬化患者按照随机数字表分成2组,对照组(n=21)给予保肝、白蛋白基础治疗,观察组(n=21)在基础治疗之上加用苦参素、胸腺肽α1治疗,疗程48周。比较2组患者治疗前后临床症状改善、Child-Pugh评分、血生化指标、HCV-RNA(hepatitis C virus-RNA)变化情况。结果对照组65.0%患者乏力消失,62.5%患者腹胀消失,50%患者腹水消失Child-Pugh评分由治疗前的(9.7±1.4)分降至治疗后的(8.3±0.7)分,观察组85.7%患者乏力消失,87.5%患者腹胀消失,88.3%患者腹水消失Child-Pugh评分由治疗前的(9.8±1.6)分降至治疗后的(5.7±0.6)分,2组临床症状改善、Child-Pugh评分差异均具有统计学意义(P<0.05);观察组患者血生化指标改善与对照组相比有统计学意义(P<0.05);对照组治疗前后HCV-RNA无显著变化,观察组治疗前后HCV-RNA有显著性差异(P<0.05)。结论苦参素联合胸腺肽α1治疗失代偿期丙型肝炎肝硬化有效降低HCV-RNA水平,延缓肝硬化进展。展开更多
Objective: To study the pharmacokinetic, distribution and elimination properties of rhTα 1 after intravenous(i.v.) and subcutaneous(s.c.)injection in mice and rats. Methods: Competition ELISA was used for testing dru...Objective: To study the pharmacokinetic, distribution and elimination properties of rhTα 1 after intravenous(i.v.) and subcutaneous(s.c.)injection in mice and rats. Methods: Competition ELISA was used for testing drug concentration in serum, urine, bile and tissue after administration of rhTα 1 in mice(0.16, 0.5, 2.5 mg/kg) and rats(0.32, 1, 5 mg/kg). Pharmacokinetic parameters were calculated by Win Nolin software. Results: Absorption of rh Tαl is rapid in both mice and rats after s.c. administration. The pharmacokinetics in mice are characterized by linear, T_(1/2) showed a prolongation with increasing dose, 1.10, 1.35, and 1.50 h corresponding to 0.32, 1 and 5 mg/kg respectively, but in rats T_(1/2) showed no difference among doses. AUC0-∞ showed a clear increase with increasing doses in mice(904.18, 2998.83, and 19001.82 h*ng/m L) and in rats(1327.56 ±237.00,2924.53 ±685.14, and 35286.26 ±5999.58 h*ng/m L). After i.v. administration of 1 mg/kg rhTα 1 in mice, the drug is seen distributed in most organs, the thymus/serum exposure ratio was higher than others at the 1 and 2 h, the accumulative urinary excretion of primary drug was 32.97% ±15.85% within 6 h. Conclusion: The results indicate that rapid absorption, extensive distribution and quick renal excretion were the basic kinetic characteristics of rh Tαl after s.c. and i.v. administration.展开更多
文摘Thymosin alpha 1 is a peptide naturally occurring in the thymus that has long been recognized for modifying,enhancing,and restoring immune function.Thymosin alpha 1 has been utilized in the treatment of immunocompromised states and malignancies,as an enhancer of vaccine response,and as a means of curbing morbidity and mortality in sepsis and numerous infections.Studies have postulated that thymosin alpha 1 could help improve the outcome in severely ill corona virus disease 2019 patients by repairing damage caused by overactivation of lymphocytic immunity and how thymosin alpha 1 could prevent the excessive activation of T cells.In this review,we discuss key literature on the background knowledge and current clinical uses of thymosin alpha 1.Considering the known biochemical properties including antibacterial and antiviral properties,timehonored applications,and the new promising findings regarding the use of thymosin,we believe that thymosin alpha 1 deserves further investigation into its antiviral properties and possible repurposing as a treatment against severe acute respiratory syndrome coronavirus-2.
文摘目的探讨苦参素联合胸腺肽α1治疗失代偿期肝硬化的抗病毒疗效。方法将42例失代偿期丙型肝炎肝硬化患者按照随机数字表分成2组,对照组(n=21)给予保肝、白蛋白基础治疗,观察组(n=21)在基础治疗之上加用苦参素、胸腺肽α1治疗,疗程48周。比较2组患者治疗前后临床症状改善、Child-Pugh评分、血生化指标、HCV-RNA(hepatitis C virus-RNA)变化情况。结果对照组65.0%患者乏力消失,62.5%患者腹胀消失,50%患者腹水消失Child-Pugh评分由治疗前的(9.7±1.4)分降至治疗后的(8.3±0.7)分,观察组85.7%患者乏力消失,87.5%患者腹胀消失,88.3%患者腹水消失Child-Pugh评分由治疗前的(9.8±1.6)分降至治疗后的(5.7±0.6)分,2组临床症状改善、Child-Pugh评分差异均具有统计学意义(P<0.05);观察组患者血生化指标改善与对照组相比有统计学意义(P<0.05);对照组治疗前后HCV-RNA无显著变化,观察组治疗前后HCV-RNA有显著性差异(P<0.05)。结论苦参素联合胸腺肽α1治疗失代偿期丙型肝炎肝硬化有效降低HCV-RNA水平,延缓肝硬化进展。
基金Natural Science Foundation of Gansu Provincegrant number:1506RJZA278
文摘Objective: To study the pharmacokinetic, distribution and elimination properties of rhTα 1 after intravenous(i.v.) and subcutaneous(s.c.)injection in mice and rats. Methods: Competition ELISA was used for testing drug concentration in serum, urine, bile and tissue after administration of rhTα 1 in mice(0.16, 0.5, 2.5 mg/kg) and rats(0.32, 1, 5 mg/kg). Pharmacokinetic parameters were calculated by Win Nolin software. Results: Absorption of rh Tαl is rapid in both mice and rats after s.c. administration. The pharmacokinetics in mice are characterized by linear, T_(1/2) showed a prolongation with increasing dose, 1.10, 1.35, and 1.50 h corresponding to 0.32, 1 and 5 mg/kg respectively, but in rats T_(1/2) showed no difference among doses. AUC0-∞ showed a clear increase with increasing doses in mice(904.18, 2998.83, and 19001.82 h*ng/m L) and in rats(1327.56 ±237.00,2924.53 ±685.14, and 35286.26 ±5999.58 h*ng/m L). After i.v. administration of 1 mg/kg rhTα 1 in mice, the drug is seen distributed in most organs, the thymus/serum exposure ratio was higher than others at the 1 and 2 h, the accumulative urinary excretion of primary drug was 32.97% ±15.85% within 6 h. Conclusion: The results indicate that rapid absorption, extensive distribution and quick renal excretion were the basic kinetic characteristics of rh Tαl after s.c. and i.v. administration.
